title: Management of inflammatory bowel disease in pregnancy.
abstract: The management of inflammatory bowel disease (IBD) in women who are pregnant or contemplating pregnancy requires special considerations. Although many of the medications in IBD treatment are generally low risk, this is not the case for all agents, and substitution of medications or adjustments in dosage or dose timing may be needed. Furthermore, while women with IBD who have not had prior pelvic surgery are as likely to conceive as non-IBD counterparts, there is evidence to suggest that pregnancy outcomes may be worse in women with IBD, particularly if they have active disease during conception or pregnancy. Therefore, a thoughtful discussion between the patient and her healthcare team is critical to ensure awareness of the possible risks of pregnancy to the mother and her infant and how these risks can be minimized with a coordinated effort in counseling, monitoring and medication adherence.
authors: Department of Gastroenterology, University of California, San Francisco, CA 94122, USA.
authors: Susie W
authors: SW
authors: Ng
authors: Uma
authors: U
authors: Mahadevan
mesh_terms: D000818:Animals; D000075202:Contraindications; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D055118:Medication Adherence; D008727:Methotrexate / Q000627:therapeutic use*; D008991:Monitoring, Physiologic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology / Q000628:therapy*; D018570:Risk Assessment
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate